1 d an angiotensin II type 1 receptor blocker (olmesartan).

2 ther an Ang II type 1 receptor blocker (ARB; olmesartan, 5 mg/d) or a triple therapy (hydralazine 7.5

3 uman AT1R in complex with an inverse agonist olmesartan (Benicar(TM)), a highly potent anti-hypertens

4 s between AT1R and different ARBs, including olmesartan derivatives with inverse agonist, neutral ant

5 uring follow-up (placebo group, 44 888 ECGs; olmesartan group, 42 930 ECGs).

6 ompassed 425 patients (placebo group, n=211; olmesartan group, n=214).

7                                              Olmesartan is anchored to the receptor primarily by the

8 PAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden

9  disease were randomized to placebo or 40 mg olmesartan per day.

10              In contrast, both captopril and olmesartan significantly improved cardiac function and r